Cardiometabolic & kidneyCross-sectional study

Cardiovascular-Kidney-Metabolic Medication Eligibility Across National Survey, Community-Based, and Ambulatory Healthcare Samples

JAMA CardiolPublished

  • Cross-sectional study
  • national survey, pooled community-based cohorts and ambulatory health care samples
  • Data analyzed November 2024 to November 2025

Authors' conclusion

This study found that up to 61% of adults met FDA-approved indications for at least 1 of 3 novel CKM therapy classes.

Study context

Population
US adults in national survey, community-based cohort and ambulatory health care samples
Exposure
NHANES vs Pooled cohorts vs BIDMC vs MGB
  • Pooled cohortsn = 30,929
  • BIDMCn = 84,714
  • MGBn = 362,485
Outcome
Medication class eligibility within each study sample

Main finding

As reported in the abstract

Eligible for ≥1 cardiovascular-kidney-metabolic (CKM) medication
GroupValueUS adults represented
NHANES60%148 million
Pooled cohorts61%
BIDMC42%
MGB46%

Observational data: associations, not effects.

Further findings

Eligible for SGLT2i

US adults represented NHANES 57.9 million

OutcomeNHANESPooled cohortsBIDMCMGB
Eligible for GLP-1RA56%49%41%
US adults represented137.1 millionNot reported in the abstractNot reported in the abstractNot reported in the abstract
Eligible for nsMRA5%5%
US adults represented11.7 millionNot reported in the abstractNot reported in the abstractNot reported in the abstract
Eligible for nsMRA — Ambulatory samples
1% to 2%

Overlapping eligibility for multiple classes

GLP-1RA and SGLT2i
12% to 17%
All 3 classes
1% to 5%
All 3 classes, US adults (NHANES)
11.7 million

Original publication

Cardiovascular-Kidney-Metabolic Medication Eligibility Across National Survey, Community-Based, and Ambulatory Healthcare Samples. JAMA Cardiol. Published 1 March 2026. doi:10.1001/jamacardio.2025.5305

Summarised from the published abstract; every number is checked against it